• Publications
  • Influence
Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats
SummaryThe pharmacokinetic characterization of DRF-4367 (a new diaryl pyrazole derivative), a potent selective COX-2 inhibitor was performed in Wistar rats. In the first study, a single dose of 2, 5,Expand
  • 1
Fast dissolving meloxicam formulation for acute dental pain: Thoughts to ponder
In the April-June issue of Asian Journal of Pharmaceutics 2008, Inamdar et al. have reported the development of a new formulation of meloxicam based on solid dispersion technique using a number ofExpand
Stavudine delivery in an extended release formulation: Will it provide the right in vivo pharmacokinetics - Some key observations
Sir, Saravanakumar et al, (2010) have performed an extensive study to enable the delivery of stavudine in a once daily extended release formulation.[1] The in vitro evaluation has been performed withExpand
Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs
SummaryA preliminary investigation into the pharmacokinetics of BMY-21502, a nootropic agent, and two of its metabolites, BMY-42191 and BMY-40440, was performed in 4 beagle dogs. Following oralExpand
FORMULATION AND EVALUATION OF MONTLUKAST SODIUM EXTENDED RELEASE MATRIX TABLET
Montelukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma, chronic asthma attacks, and to relieve symptoms of seasonal allergies. It is usually administered orallyExpand